Petal Consortium

— Our Mission —

"No patient with peripheral T-cell lymphoma is left behind."

— Dr. Salvia Jain, Founder of PETAL Consortium —

What is Peripheral T-cell Lymphoma?

Peripheral T-cell lymphoma (PTCL) is a rare and aggressive blood cancer, with about 7,000 new cases diagnosed in the US annually. Lymphoma is cancer of the lymphocytes, a type of white blood cell within the immune system. Peripheral T cells are a type of lymphocyte that destroy tumor cells and are found in the body's blood, lymph nodes, spleen, and other organs. Basically, PTCL is cancer of the cancer-fighting cells in the body.

What is PETAL Consortium?

In 2023, Salvia Jain, MD, a hematologist-oncologist at Massachusetts General Hospital, recognized the lack of systematic, multimodal longitudinal data for patients with peripheral T-cell lymphoma (PTCL). In response, she founded PETAL Consortium—a first-of-its-kind global network dedicated to advancing care for this rare and aggressive blood cancer by serving as a central hub of information.

PTCL’s rarity has significantly impeded research efforts and clinical trial development in a reasonable timeframe. PETAL overcomes this challenge by uniting leading centers of excellence in PTCL clinical care and research worldwide, enabling investigators to generate, collate, and access data from hundreds of patients.

Today, PETAL brings together more than 100 investigators from over 20 international research sites–spanning lymphoma medicine, artificial intelligence, systems biology, pathology, genomics, biostatistics, and bioinformatics–to accelerate discovery and transform how PTCL is understood and treated.

0+

Patients represented in PETAL research datasets

0+

Clinicians and investigators working across institutions

0+

Leading cancer centers participating in PETAL Consortium

0+

Rare T-cell lymphoma subtypes studied across global cohorts

0+

Multidisciplinary specialties including oncology, pathology, genomics, and AI

0+

Peer-reviewed research publications in high-impact factor journals within 2 years generated through PETAL collaborations

Research

Our mission is to create a centralized hub that integrates clinical, pathologic, treatment, radiologic, and molecular data into a comprehensive, multimodal dataset–enabling more precise, personalized treatment recommendations for patients.

Learn More

Discovery & Innovation

We use cutting edge artificial intelligence and next generation sequencing technologies to identify new targets for drug development in collaboration with biotechnology and pharmaceutical partners.

Learn More

Clinical Trials

PTCL’s heterogeneity, complexity and rarity has hindered development of clinical trials and accrual. PETAL addresses this barrier by providing a global clinical trial framework, adapting novel trial designs and modernizing protocols.

Learn More

Patient Care & Support

HOPE-PTCL (Hub for Outreach and Patient Engagement in Peripheral T-cell Lymphoma) is PETAL’s patient education website, dedicated to empowering and connecting individuals and families affected by PTCL through knowledge, compassion, and community.

Visit HOPE-PTCL

Newsroom

SEPTEMBER 2026

Blood Cancer Awareness Month

Check out our Blood Cancer Awareness Month Q&A with Salvia Jain, MD, founder of PETAL Consortium and hematologist-oncologist at Massachusetts General Hospital!

SEPTEMBER 2026

Blood Cancer Awareness Month

After the deaths of ‘Jurassic Park’ actor Sam Neill and Chinese economist Gao Shanwen, we are shining a light on angioimmunoblastic T-cell lymphoma, a rare and aggressive subtype of peripheral T-cell lymphoma.

AUGUST 2026

How a multidisciplinary team helped a paralyzed cancer patient walk again

After being diagnosed with peripheral T-cell lymphoma, James experienced rapid physical decline that left him unable to walk. Through treatment and rehabilitation, James gradually regained his strength, mobility, and independence. Today, he is back on his feet and even mowing his own lawn. His story highlights the impact of comprehensive, patient-centered cancer care that addresses both the disease and the person behind the diagnosis.

How a multidisciplinary team helped a paralyzed cancer patient walk again

JULY 2026